Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists

Darren M. Riddy, Anna E. Cook, David M. Shackleford, Tracie L. Pierce, Elisabeth Mocaer, Clotilde Mannoury la Cour, Aurore Sors, William N. Charman, Roger J. Summers, Patrick M. Sexton, Arthur Christopoulos, Christopher J. Langmead

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The histamine H3 receptor is a G protein-coupled receptor (GPCR) drug target that is highly expressed in the CNS, where it acts as both an auto- and hetero-receptor to regulate neurotransmission. As such, it has been considered as a relevant target in disorders as varied as Alzheimer's disease, schizophrenia, neuropathic pain and attention deficit hyperactivity disorder. A range of competitive antagonists/inverse agonists have progressed into clinical development, with pitolisant approved for the treatment of narcolepsy. Given the breadth of compounds developed and potential therapeutic indications, we assessed the comparative pharmacology of six investigational histamine H3 agents, including pitolisant, using native tissue and recombinant cells. Whilst all of the compounds tested displayed robust histamine H3 receptor inverse agonism and did not differentiate between the main H3 receptor splice variants, they displayed a wide range of affinities and kinetic properties, and included rapidly dissociating (pitolisant, S 38093-2, ABT-239) and slowly dissociating (GSK189254, JNJ-5207852, PF-3654746) agents. S 38093-2 had the lowest histamine H3 receptor affinity (pKB values 5.7–6.2), seemingly at odds with previously reported, potent in vivo activity in models of cognition. We show here that at pro-cognitive and anti-hyperalgesic/anti-allodynic doses, S 38093-2 preferentially occupies the mouse sigma-1 receptor in vivo, only engaging the histamine H3 receptor at doses associated with wakefulness promotion and neurotransmitter (histamine, ACh) release. Furthermore, pitolisant, ABT-239 and PF-3654746 also displayed appreciable sigma-1 receptor affinity, suggesting that this property differentiates clinically evaluated histamine H3 receptor antagonists and may play a role in their efficacy.

Original languageEnglish
Pages (from-to)244-255
Number of pages12
JournalNeuropharmacology
Volume144
DOIs
Publication statusPublished - 1 Jan 2019

Keywords

  • Histamine H receptor
  • Kinetics
  • Receptor occupancy
  • S 38093-2
  • Sigma-1 receptor

Cite this

@article{90c21dfa2179493dac3fae52a147dfc1,
title = "Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists",
abstract = "The histamine H3 receptor is a G protein-coupled receptor (GPCR) drug target that is highly expressed in the CNS, where it acts as both an auto- and hetero-receptor to regulate neurotransmission. As such, it has been considered as a relevant target in disorders as varied as Alzheimer's disease, schizophrenia, neuropathic pain and attention deficit hyperactivity disorder. A range of competitive antagonists/inverse agonists have progressed into clinical development, with pitolisant approved for the treatment of narcolepsy. Given the breadth of compounds developed and potential therapeutic indications, we assessed the comparative pharmacology of six investigational histamine H3 agents, including pitolisant, using native tissue and recombinant cells. Whilst all of the compounds tested displayed robust histamine H3 receptor inverse agonism and did not differentiate between the main H3 receptor splice variants, they displayed a wide range of affinities and kinetic properties, and included rapidly dissociating (pitolisant, S 38093-2, ABT-239) and slowly dissociating (GSK189254, JNJ-5207852, PF-3654746) agents. S 38093-2 had the lowest histamine H3 receptor affinity (pKB values 5.7–6.2), seemingly at odds with previously reported, potent in vivo activity in models of cognition. We show here that at pro-cognitive and anti-hyperalgesic/anti-allodynic doses, S 38093-2 preferentially occupies the mouse sigma-1 receptor in vivo, only engaging the histamine H3 receptor at doses associated with wakefulness promotion and neurotransmitter (histamine, ACh) release. Furthermore, pitolisant, ABT-239 and PF-3654746 also displayed appreciable sigma-1 receptor affinity, suggesting that this property differentiates clinically evaluated histamine H3 receptor antagonists and may play a role in their efficacy.",
keywords = "Histamine H receptor, Kinetics, Receptor occupancy, S 38093-2, Sigma-1 receptor",
author = "Riddy, {Darren M.} and Cook, {Anna E.} and Shackleford, {David M.} and Pierce, {Tracie L.} and Elisabeth Mocaer and {Mannoury la Cour}, Clotilde and Aurore Sors and Charman, {William N.} and Summers, {Roger J.} and Sexton, {Patrick M.} and Arthur Christopoulos and Langmead, {Christopher J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.neuropharm.2018.10.028",
language = "English",
volume = "144",
pages = "244--255",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier",

}

Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists. / Riddy, Darren M.; Cook, Anna E.; Shackleford, David M.; Pierce, Tracie L.; Mocaer, Elisabeth; Mannoury la Cour, Clotilde; Sors, Aurore; Charman, William N.; Summers, Roger J.; Sexton, Patrick M.; Christopoulos, Arthur; Langmead, Christopher J.

In: Neuropharmacology, Vol. 144, 01.01.2019, p. 244-255.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists

AU - Riddy, Darren M.

AU - Cook, Anna E.

AU - Shackleford, David M.

AU - Pierce, Tracie L.

AU - Mocaer, Elisabeth

AU - Mannoury la Cour, Clotilde

AU - Sors, Aurore

AU - Charman, William N.

AU - Summers, Roger J.

AU - Sexton, Patrick M.

AU - Christopoulos, Arthur

AU - Langmead, Christopher J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The histamine H3 receptor is a G protein-coupled receptor (GPCR) drug target that is highly expressed in the CNS, where it acts as both an auto- and hetero-receptor to regulate neurotransmission. As such, it has been considered as a relevant target in disorders as varied as Alzheimer's disease, schizophrenia, neuropathic pain and attention deficit hyperactivity disorder. A range of competitive antagonists/inverse agonists have progressed into clinical development, with pitolisant approved for the treatment of narcolepsy. Given the breadth of compounds developed and potential therapeutic indications, we assessed the comparative pharmacology of six investigational histamine H3 agents, including pitolisant, using native tissue and recombinant cells. Whilst all of the compounds tested displayed robust histamine H3 receptor inverse agonism and did not differentiate between the main H3 receptor splice variants, they displayed a wide range of affinities and kinetic properties, and included rapidly dissociating (pitolisant, S 38093-2, ABT-239) and slowly dissociating (GSK189254, JNJ-5207852, PF-3654746) agents. S 38093-2 had the lowest histamine H3 receptor affinity (pKB values 5.7–6.2), seemingly at odds with previously reported, potent in vivo activity in models of cognition. We show here that at pro-cognitive and anti-hyperalgesic/anti-allodynic doses, S 38093-2 preferentially occupies the mouse sigma-1 receptor in vivo, only engaging the histamine H3 receptor at doses associated with wakefulness promotion and neurotransmitter (histamine, ACh) release. Furthermore, pitolisant, ABT-239 and PF-3654746 also displayed appreciable sigma-1 receptor affinity, suggesting that this property differentiates clinically evaluated histamine H3 receptor antagonists and may play a role in their efficacy.

AB - The histamine H3 receptor is a G protein-coupled receptor (GPCR) drug target that is highly expressed in the CNS, where it acts as both an auto- and hetero-receptor to regulate neurotransmission. As such, it has been considered as a relevant target in disorders as varied as Alzheimer's disease, schizophrenia, neuropathic pain and attention deficit hyperactivity disorder. A range of competitive antagonists/inverse agonists have progressed into clinical development, with pitolisant approved for the treatment of narcolepsy. Given the breadth of compounds developed and potential therapeutic indications, we assessed the comparative pharmacology of six investigational histamine H3 agents, including pitolisant, using native tissue and recombinant cells. Whilst all of the compounds tested displayed robust histamine H3 receptor inverse agonism and did not differentiate between the main H3 receptor splice variants, they displayed a wide range of affinities and kinetic properties, and included rapidly dissociating (pitolisant, S 38093-2, ABT-239) and slowly dissociating (GSK189254, JNJ-5207852, PF-3654746) agents. S 38093-2 had the lowest histamine H3 receptor affinity (pKB values 5.7–6.2), seemingly at odds with previously reported, potent in vivo activity in models of cognition. We show here that at pro-cognitive and anti-hyperalgesic/anti-allodynic doses, S 38093-2 preferentially occupies the mouse sigma-1 receptor in vivo, only engaging the histamine H3 receptor at doses associated with wakefulness promotion and neurotransmitter (histamine, ACh) release. Furthermore, pitolisant, ABT-239 and PF-3654746 also displayed appreciable sigma-1 receptor affinity, suggesting that this property differentiates clinically evaluated histamine H3 receptor antagonists and may play a role in their efficacy.

KW - Histamine H receptor

KW - Kinetics

KW - Receptor occupancy

KW - S 38093-2

KW - Sigma-1 receptor

UR - http://www.scopus.com/inward/record.url?scp=85055886619&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2018.10.028

DO - 10.1016/j.neuropharm.2018.10.028

M3 - Article

VL - 144

SP - 244

EP - 255

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -